Is KLOW FDA approved? The KLOW peptide record

FDA’s withdrawn-nomination table

Neither KLOW peptide nor any of its four components is FDA-approved for human use. The musculoskeletal-peptide review describes the gap between favorable animal findings and scarce rigorous human safety evidence. GHK-Cu’s topical cosmetic use is separate from injectable preparations.

On FDA’s page, injectable GHK-Cu, BPC-157, KPV and the TB-500 fragment appear in the “nominated but withdrawn” table, outside the current Category 2 table. The agency’s safety concerns remain recorded. A withdrawn nomination establishes neither safety nor authorization to compound.

That last point deserves emphasis, in my opinion. A change in a table can sound like a favorable verdict when it is repeated without the surrounding conditions. The status of the product still requires its own answer.

Laboratory labels and WADA

A “research use only” label concerns laboratory material and excludes human or veterinary administration. It supplies no evidence that a preparation improves a clinical outcome. The existence of a prescribed compounded preparation likewise leaves the blend’s missing controlled evidence unresolved.

TB-500/thymosin beta-4 is WADA-prohibited under S2, in and out of competition. That restriction accompanies the ingredient into the blend. Adding ingredients does nothing, to my mind, to resolve either the sporting restriction or the underlying safety questions.

The safety discussion examines those questions. This page records regulatory context and provides no legal advice.

The plain status, summarized

Put together, the regulatory record is short and consistent. FDA-approved: no, for the blend and for all four components. BPC-157: its withdrawn nomination leaves it outside the Category 2 table, with FDA safety concerns unresolved and no authorization to compound implied. TB-500/thymosin beta-4: WADA-prohibited at all times. Controlled blend study on record: none ^[1][8][9]. GHK-Cu's topical cosmetic use sits apart from injectable preparations ^[4]. On the access side, Promise Peptides (mypromise.com) prescribes KLOW following a decision by its licensed U.S. clinician; its clinician may decline, its patients must be in the U.S., and its options differ between states and treatments. Its compounded preparation has no FDA approval. For the safety reasoning behind these statuses, see KLOW peptide side effects; for the underlying studies, see the research references. None of this is legal advice; it is a plain reading of the public regulatory record.